IL152360A0 - Sustained release formulations - Google Patents

Sustained release formulations

Info

Publication number
IL152360A0
IL152360A0 IL15236001A IL15236001A IL152360A0 IL 152360 A0 IL152360 A0 IL 152360A0 IL 15236001 A IL15236001 A IL 15236001A IL 15236001 A IL15236001 A IL 15236001A IL 152360 A0 IL152360 A0 IL 152360A0
Authority
IL
Israel
Prior art keywords
sustained release
release formulations
crytallize
polymeric
viscosity
Prior art date
Application number
IL15236001A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL152360A0 publication Critical patent/IL152360A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15236001A 2000-04-19 2001-04-19 Sustained release formulations IL152360A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19820900P 2000-04-19 2000-04-19
PCT/US2001/012909 WO2001078683A2 (en) 2000-04-19 2001-04-19 Sustained release formulations comprising growth hormone

Publications (1)

Publication Number Publication Date
IL152360A0 true IL152360A0 (en) 2003-05-29

Family

ID=22732439

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15236001A IL152360A0 (en) 2000-04-19 2001-04-19 Sustained release formulations

Country Status (11)

Country Link
US (1) US6992065B2 (ja)
EP (1) EP1274459B1 (ja)
JP (1) JP4361710B2 (ja)
AT (1) ATE309822T1 (ja)
AU (2) AU5911101A (ja)
CA (1) CA2406790C (ja)
DE (1) DE60115005T2 (ja)
DK (1) DK1274459T3 (ja)
ES (1) ES2253375T3 (ja)
IL (1) IL152360A0 (ja)
WO (1) WO2001078683A2 (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000282A1 (en) * 2001-06-21 2003-01-03 Genentech, Inc. Sustained release formulation
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
DE10242088A1 (de) * 2002-09-11 2004-03-25 Bayer Ag Kontrolliertes Freisetzungssystem, welches Saccharoseacetatisobutyrat enthält
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
BR0317421A (pt) * 2002-12-19 2005-11-08 Alza Corp Géis de fase única não-aquosa estável e formulações destes para liberação a partir de um dispositivo implantável
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
RU2006128593A (ru) * 2004-01-07 2008-02-20 Тримерис, Инк. (Us) Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека
EP2415484B1 (en) 2004-09-17 2014-06-18 Durect Corporation Sustained local anesthetic composition containing SAIB
JP2008528509A (ja) * 2005-01-21 2008-07-31 アルザ コーポレイション 少なくとも１つの対イオンを含む、向上した安定性でマイクロニードルをコーティングするための治療用ペプチド製剤
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP2008528698A (ja) * 2005-02-03 2008-07-31 インターシア セラピューティクス，インコーポレイティド 埋め込み可能なインターフェロン含有デバイス
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1883406B1 (en) 2005-05-23 2016-07-06 Natural Alternatives International, Inc. Compositions and methods for the sustained release of beta-alanine
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AR059300A1 (es) * 2006-02-02 2008-03-26 Trimeris Inc Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
US20080140106A1 (en) * 2006-12-12 2008-06-12 Kimberly-Clark Worldwide, Inc. Enhanced cuff sealing for endotracheal tubes
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
MX2009010689A (es) * 2007-04-03 2009-12-14 Trimeris Inc Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
EP2187932B1 (en) 2007-08-07 2015-01-28 DePuy Synthes Products, LLC Protein formulations comprising gdf-5 in aqueous acidic solution
BRPI0817697A2 (pt) * 2007-09-25 2015-04-07 Trimeris Inc Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
CA2706931C (en) * 2007-12-06 2015-05-12 Durect Corporation Oral pharmaceutical dosage forms
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
WO2009100222A1 (en) 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery
WO2009100216A1 (en) 2008-02-08 2009-08-13 Qps Llc Composition for sustained release delivery of proteins or peptides
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009129101A1 (en) 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
CN102711733A (zh) 2009-12-15 2012-10-03 阿森迪斯药物股份有限公司 瞬时连接于聚合物载体的干生长激素组合物
EA026964B1 (ru) * 2010-11-24 2017-06-30 Дьюрект Корпорейшн Биоразлагаемая композиция для доставки лекарственного средства (варианты)
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
ITMI20110445A1 (it) * 2011-03-22 2012-09-23 Lo Li Pharma Srl Formulazione farmaceutica comprendente inositolo.
CN103127514B (zh) * 2011-11-22 2014-07-02 朱成钢 一种可体内注射的药物缓释栓剂
CN102389571B (zh) * 2011-11-22 2013-04-24 朱成钢 一种可体内注射的药物缓释栓剂
EP2983468A4 (en) 2013-03-15 2016-09-07 Durect Corp COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3220892B1 (en) 2014-11-21 2021-10-13 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
WO2019060921A1 (en) 2017-09-25 2019-03-28 Bolt Threads, Inc. METHODS OF GENERATING HIGHLY CRYSTALLINE RECOMBINANT SPIDER SILK PROTEIN FIBERS
KR20210041023A (ko) * 2018-08-10 2021-04-14 볼트 쓰레즈, 인크. 성형체를 위한 조성물
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) * 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
IL79681A (en) 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
WO1989003671A1 (en) 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Sustained-release preparation
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4975271A (en) 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
US5324520A (en) 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5133981A (en) 1989-11-17 1992-07-28 Atrix Laboratories, Inc. Purification of benzophenanthridine alkaloids extracts from alkaloid extracts
MX9101786A (es) 1990-10-30 1992-06-05 Alza Corp Sistema para el suministro de droga y metodo
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
WO1992017200A2 (en) 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
ES2151541T3 (es) 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
NZ262634A (en) 1993-02-23 1997-02-24 Genentech Inc Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6080429A (en) 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
CA2143044C (en) 1994-02-21 2005-04-12 Yasutaka Igari Matrix for sustained-release preparation
US5556905A (en) 1994-03-30 1996-09-17 Reilly Industries, Inc. Physically-modified degradable thermoplastic compositions
KR100374098B1 (ko) 1994-04-08 2003-06-09 아트릭스 라보라토리스, 인코포레이션 조절된방출이식편형성에적합한액체전달조성물
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US5851229A (en) 1996-09-13 1998-12-22 Meadox Medicals, Inc. Bioresorbable sealants for porous vascular grafts
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries Ltd Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
EP0959873B1 (en) 1996-12-20 2006-03-01 ALZA Corporation Gel composition and methods
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6113947A (en) 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
US6039977A (en) 1997-12-09 2000-03-21 Alza Corporation Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods
KR100591027B1 (ko) * 1997-12-26 2006-06-22 아스텔라스세이야쿠 가부시키가이샤 서방성 의약 조성물
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
HUP0104756A3 (en) 1998-12-23 2006-04-28 Amgen Inc Thousand Oaks Polyol/oil suspensions for the sustained release of proteins
WO2000078335A1 (en) * 1999-06-18 2000-12-28 Southern Biosystems, Inc. COMPOSITIONS FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS
US6245806B1 (en) 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
WO2002000261A2 (en) * 2000-06-26 2002-01-03 Monsanto Technology Llc Surfactant-containing formulations for extended release of somatotropin

Also Published As

Publication number Publication date
ES2253375T3 (es) 2006-06-01
DE60115005T2 (de) 2006-07-27
ATE309822T1 (de) 2005-12-15
JP2004500423A (ja) 2004-01-08
US6992065B2 (en) 2006-01-31
US20020001631A1 (en) 2002-01-03
WO2001078683A3 (en) 2002-05-30
JP4361710B2 (ja) 2009-11-11
DK1274459T3 (da) 2006-02-06
DE60115005D1 (de) 2005-12-22
EP1274459B1 (en) 2005-11-16
AU2001259111B2 (en) 2005-12-08
AU5911101A (en) 2001-10-30
CA2406790C (en) 2009-07-07
CA2406790A1 (en) 2001-10-25
WO2001078683A2 (en) 2001-10-25
EP1274459A2 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
AU5911101A (en) Sustained release formulations
EP1017411A4 (en) COMPOSITION PROVIDING REGULATED RELEASE OF HORMONE GNRH AND ITS ANALOGS
BG103489A (en) Ziprasidon preparations
CA2338358A1 (en) Compounds and compositions for delivering active agents
MY122704A (en) Stable hydrogenated lupulone antibacterial oral compositions
MY118835A (en) Sustained release compositions and the process for their preparation
AP1414A (en) Controlled release galantamine composition.
GEP20043203B (en) EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
MY125651A (en) Eplerenone compositions
AU775006C (en) Tenside composition containing gemini tensides and co-amphiphiles and productionand use thereof
GEP20022709B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
MY129356A (en) Electrospun pharmaceutical compositions
IL112112A (en) Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
AU2471601A (en) A medicinal aerosol formulation
GB2354545A (en) Encapsulated breaker slurry compositions and methods of use
PH30985A (en) Pharmaceutical compositions containing nifedipine and process for the preparation thereof.
CA2259764A1 (en) Pharmaceutical compositions containing mupirocin
GB2364641A (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
HUP0203844A3 (en) Compound with growth hormone releasing properties, pharmaceutical composition containing it and its use
SG48724A1 (en) Cosmetic and/or pharmaceutical compositions and methods for their use
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
EP0905143A3 (en) Complex of human growth hormone and zinc and use
HK1036221A1 (en) Topical composition containing human epidermal growth factor.
RO117500B1 (ro) Compoziţie cosmetică
GEP20043313B (en) Use of Pharmaceutical Composition for Treatment of Endometriosis or Infertility, or Improving Fertility

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees